PeptidePros
All Peptides

Research Hub

Skin, Hair & Appearance

Find compounds researched for skin quality, visible recovery, pigmentation, collagen support, and cosmetic-adjacent outcomes.

skin qualityhair supportappearancecollagen signaling
5
Peptides
3
Vendors
4
Guides
$80.00
Cycle cost

Overview

Find compounds researched for skin quality, visible recovery, pigmentation, collagen support, and cosmetic-adjacent outcomes.

Peptides tracked

5 of 46 published compounds

Cycle cost

$80.00

Goals covered

Skin & Hair

Outcomes

skin quality, hair support, appearance, collagen signaling

Goal hub next step

Build a skin, hair & appearance research path.

Use the quiz before choosing a compound, vendor, or PDF so the route reflects your goal, risk tolerance, and monitoring comfort.

Best options to research first

Ranked by evidence first, then risk. A research starting point, not a clinical recommendation.

Compare top

Melanotan I

FDA-approved MC1R agonist (SCENESSE implant) for erythropoietic protoporphyria. Prescription only.

Tier Amedium riskadvanced
Routes

subcutaneous implant

Timeline

Controlled-release kinetics; plasma concentrations up to ~96 hours in most subjects.

Vendor listings

2 tracked

GHK-Cu

Copper peptide complex with substantial topical/cosmetic literature for skin and hair repair.

Tier B-Cmed-high riskbeginner
Routes

topical

Timeline

Skin remodeling: weeks to months (collagen turnover cycles).

Cycle cost

$60.00

Vendor listings

3 tracked

LL-37

Human antimicrobial peptide with topical wound healing studies. Antimicrobial therapeutic claims trigger regulatory scrutiny.

Tier B-Chigh riskintermediate
Routes

topical

Timeline

Wound endpoints measured over weeks.

Vendor listings

0 tracked

KPV

Anti-inflammatory α-MSH tripeptide fragment studied in cell and animal models for NF-κB inhibition.

Tier Cmed-high riskintermediate
Routes

topical, subcutaneous

Timeline

Cell signaling endpoints are acute; clinical translation unknown.

Cycle cost

$31.99

Vendor listings

3 tracked

Melanotan II

Unlicensed broad melanocortin agonist with pigmentation and sexual side-effect profiles. Highest compliance risk.

Tier Chigh riskadvanced
Routes

subcutaneous

Timeline

Pigmentation changes can occur quickly; adverse events can be acute.

Cycle cost

$80.00

Vendor listings

3 tracked

Higher-risk options

LL-37high

Topical appears tolerable; systemic use carries different risk profile.

FDA cites serious adverse events: melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, priapism. Immunogenicity/impurity concerns.

Trusted vendors for skin and cosmetic research

These vendors currently carry compounds in this goal category. Hub is the trust layer; outbound clicks happen after comparison.

Amino Club

4 relevant compounds in hub

Review
COA

product page COA viewer

QC

third-party purity testing; product-level COA on page

Shipping

US/ROW (verify current policy)

Affiliate

affiliate: public program

XL Peptides

4 relevant compounds in hub

Review
COA

testing reports on product page

QC

third-party testing reports linked on product page

Shipping

UK, Europe, and rest of world via vendor shipping options

Affiliate

affiliate: direct product page

Ignite Peptides

3 relevant compounds in hub

Review
COA

COA with order / verify current product report

QC

third-party testing and COA documentation claimed by vendor; verify product-specific report

Shipping

U.S. domestic territories only

Affiliate

affiliate: direct product page

Sources and review notes

  1. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15

    Used for FDA compounding-risk context and peptide safety flags.

  2. The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15

    Used for athlete-facing WADA risk and peptide-class restrictions.

  3. Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15

    Used for broad peptide-therapeutics background and evidence framing.